The effects of local 17b-oestradiol therapy on the vaginal mucosa and endometrial thickness were studied in 35 postmenopausal women with symptoms of vaginal atrophy. Signs and symptoms of vaginal atrophy were measured by anamnesis, visual examination and the maturation index before and after 12 weeks' treatment with 17b-oestradiol in the form of vaginal tablets. The maturation proportion on vaginal smear, endometrial thickness on transvaginal ultrasonography and plasma concentrations of folliclestimulating hormone, luteinizing hormone and oestradiol were also determined. All vaginal atrophy signs and symptoms significantly improved and there was a significant increase in vaginal smear maturation with 17b-oestradiol treatment. Endometrial thickness did not change significantly. It is concluded that 17boestradiol improves the signs and symptoms of vaginal atrophy without causing endometrial stimulation and offers a safe and effective alternative to systemic hormone replacement therapy for the treatment of vaginal symptoms associated with post-menopausal oestrogen deficiency.
Introduction
In recent years there has been increased interest in the climacteric and postmenopausal period, partly due to longer life spans and better standards of living. The menopause is a physiological event that is characterized by oestrogen deficiency and its associated effects, which include atrophy of the urogenital system, vasomotor symptoms, osteoporosis in later years and an increased risk of cardiovascular disease.
Hormone replacement therapy (HRT) is an established treatment for symptoms of oestrogen deficiency. 1 -3 The concentrations of oestrogen used in systemic HRT affect the vaginal mucosa, relieving vaginal symptoms, however many patients do not require systemic HRT, and local treatment with oestrogens can be used, for example for atrophic vaginitis. Symptoms can recur after treatment ends, however local oestrogen therapy has the advantage that it can be given over a long period. A disadvantage is that locally applied oestrogen preparations AE Yumru, M Bozkurt, E Inci Coşkun et al. 17b-Oestradiol for post-menopausal vaginal symptoms are not effective for improving long-term risk of osteoporosis or cardiovascular disease. 3 The aims of the present study were to investigate the efficacy of intravaginal lowdose 17β-oestradiol in post-menopausal women with genital atrophy for the treatment of local vaginal symptoms, and to look at the stimulant effect of this therapy on the endometrium.
Patients and methods

PATIENTS
Patients with symptoms of vaginal atrophy were recruited from the Obstetrics and Gynaecology Clinics of Taksim Education and Research Hospital, Istanbul, Turkey. Women who had previously undergone hysterectomy, who had serious systemic or psychiatric illness, breast or genital malignancies, pre-cancerous lesions or genital system hyperplasia, undefined vaginal haemorrhagia or a history of thromboembolic disease or HRT were excluded from the study.
The study protocol was approved by the ethical committee at Taksim Education and Research Hospital. Written and verbal consent was obtained from all patients prior to their participation in the study.
TREATMENT
All patients were given local 17β-oestradiol therapy for 12 weeks. For the first 14 days, 25 µg 17β-oestradiol was given daily as a vaginal tablet, followed by 25 µg 17βoestradiol, also given as a vaginal tablet, twice weekly for a further 10 weeks.
PATIENT ASSESSMENTS
Symptoms and signs of vaginal atrophy, the maturation proportion in a vaginal smear, endometrial thickness and plasma concentrations of oestradiol, folliclestimulating hormone (FSH) and luteinizing hormone (LH) were measured before and after the treatment period.
Subjective vaginal symptoms of vaginal atrophy, including vaginal dryness, burning, itching and dyspareunia were graded by the patients as 'none', 'mild', 'moderate' or 'severe'. Signs of vaginal atrophy on gynaecological examination were classified subjectively by the physician using the visual criteria of paleness of the vaginal mucosa, flattening in the vaginal rugae, narrowing and shortening of the vagina, and the existence or absence of petechial haemorrhages.
Smear specimens were taken from the upper part of the lateral vaginal walls and the percentages of superficial, intermediate and parabasal cells were determined. The maturation proportion was then calculated using the following formula:
Endometrial thickness was measured using transvaginal ultrasonography; the widest anterior-posterior diameter in the longitudinal position was recorded. In patients with an endometrial thickness ≥ 5 mm, an endometrial biopsy was performed using a Pipelle ® cannula (Cooper Surgical, Trumbull, CT, USA) and evaluated histopathologically.
DATA ANALYSIS
Findings before and after treatment were compared using the χ 2 test, Wilcoxon test and Student's t-test. A P-value < 0.05 was considered to be statistically significant. Table 1 . The mean menopause duration was 9.4 years (range 3 -20 years); the distribution of patients according to menopausal duration is given in Table 2 .
Results
The mean ± SD maturation proportion in the vaginal smear was 21.70 ± 9.98% before treatment and 51.90 ± 4.66 after treatment (P < 0.001, Student's t-test). The distribution of patients according to maturation proportion is given in Table 3 .
The numbers of patients with symptoms and signs of vaginal atrophy are shown in Table 4 ; all the evaluated symptoms and signs on examination were significantly improved after treatment with local 17βoestradiol (P < 0.001, χ 2 test). In some patients the symptoms were resistant to treatment, with severe burning remaining in one patient, severe itching in two patients and severe dyspareunia in two patients. One 51-year-old patient did not comply with the prescribed therapy and presented 1 week later with persistent itching. She was 5 years' post-menopausal and had not previously received any treatment for her vaginal symptoms. At the second visit, a dose of 17βoestradiol was applied in the clinic and the patient expressed that she had not previously administered the prescribed medicine properly. After 12 weeks of local 17β-oestradiol treatment, this patient's vaginal symptoms improved significantly.
The mean ± SD endometrial thickness was 2.24 ± 1.29 mm before treatment and 2.41 ± 1.46 mm after treatment. This difference was not statistically significant, however the critical limit for endometrial thickness in the present study was 5 mm, below which it was regarded as atrophic, and both these values are a lot smaller than 5 mm. The distribution of patients according to endometrial thickness is given in Table 5 . In two patients, the endometrial thickness was 6.1 and 5.4 mm before treatment and 5.3 and 5.0 mm, respectively, after treatment. Endometrial biopsy results before and after treatment showed 'proliferative endometrium' in both patients. In a further two patients, the endometrial thickness was 3.9 and 3.7 mm before treatment and 5.1 and 5.6 mm, respectively, after treatment; endometrial biopsy results showed 'atrophic endometrium'.
The plasma concentrations of FSH, LH and oestradiol before and after treatment are given in Table 6 . Oestradiol levels rose very slightly (not statistically significant) but remained within the normal postmenopausal range. No relationship was seen between the maturation proportion and the increase in plasma oestradiol concentration.
Discussion
Post-menopausal atrophic vaginitis is a common problem: symptoms such as vaginal dryness, burning, itching and dyspareunia occur in 20 -30% of postmenopausal women. 4 -6 Various oestrogen preparations have been shown to be effective treatments. 7 Ever having used HRT has been reported in 37% of all women > 60 years of age in a USA study but this was affected by multiple factors such as family income, education and race, and vaginal oestrogen preparations still needed to be used for symptoms of vaginal atrophy. 8 Low-dose oestrogen therapy can be used to treat urogenital atrophy caused by oestrogen deficiency, without stimulation of the endometrium. 9 Speroff et al. 10 reported that the dose of oestrogen required to induce proliferation in the vaginal epithelium in post-menopausal women is lower than that associated with endometrial proliferation. Vaginal oestrogen regimens have the advantage that, in addition to not causing endometrial stimulation, they do not require 11 Studies have investigated whether exogenous oestrogen is associated with an increased risk for endometrial malignancy. 12, 13 It has been reported that vaginal conjugated oestrogens and oestrone sulphate cause significant endometrial proliferation and hyperplasia, but not cancer. 12 -14 The present study on the efficacy of local 17β-oestradiol for relieving symptoms of vaginal atrophy and whether it was associated with endometrial hyperplasia in post-menopausal women showed a significant improvement in the symptoms of vaginal atrophy, which is consistent with other studies. 15 -17 On gynaecological examination, the signs of vaginal atrophy were attenuated in all the patients originally classified as having severe atrophy.
Vaginal cytology demonstrated evidence of maturation: almost all of the parabasal cells disappeared and were replaced by intermediate and superficial cells. The vaginal smear maturation proportion after treatment was significantly higher than before treatment, which is consistent with previously published literature showing that vaginal 17β-oestradiol produces a significant increase in vaginal smear maturation. 18 The small changes in the plasma concentrations of FSH and LH, although statistically significant, were not clinically relevant. The change in oestradiol level was not statistically significant and also was not significant clinically. Similar results have been reported previously. 19, 20 The critical limit for endometrial thickness in the present study was 5 mm, below which it was regarded as atrophic. Since the mean endometrial thickness was below this value both before and after treatment, it is clear that the endometrium remained atrophic so 17β-oestradiol did not lead to a significant change in endometrial thickness. Although endometrial thickness increased in two patients to > 5 mm, biopsies in both cases still showed atrophic endometrium.
In a study by Mettler and Olsen, 14 24 patients with vaginal atrophy symptoms were treated with 25 µg 17β-oestradiol once or twice weekly for 2 years and endometrial biopsies before and after treatment were compared. Weak proliferative changes were seen in only four patients and the authors concluded that vaginal 17β-oestradiol was a safe and efficient alternative to systemic treatment, with very little risk. This was also supported in a study by Martin et al. 21 and is consistent with the results of the present study.
This study has the limitation that it did not include a 'no treatment' control group, however the symptoms of vaginal atrophy are known to worsen with time. Further research for the assessment of the effects of local oestrogen treatment involving a control group made up of patients who refuse treatment is planned.
In conclusion, this study demonstrated that local 17β-oestradiol therapy in postmenopausal women improved the signs of vaginal atrophy and diminished the subjective vaginal symptoms of dryness, burning, itching and dyspareunia without inducing endometrial stimulation. Local lowdose 17β-oestradiol is, therefore, a safe and effective alternative to systemic HRT for the treatment of vaginal symptoms associated with post-menopausal oestrogen deficiency.
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